Persistent fatigue
Advancing the
Management of
ANAEMIA
IN CHRONIC
KIDNEY DISEASE
An oral HIF-PH inhibitor designed to help improve haemoglobin levels in CKD patients through stimulation of endogenous erythropoietin production.
For use in appropriate patients under medical supervision.Oral Therapy
Convenient once-daily oral administration
HIF-PH Inhibitor
Targets the underlying cause of anaemia in CKD
CKD Anaemia Management
Improves haemoglobin levels effectively
Dialysis & Non-Dialysis Patients
Designed for a broad range of CKD patients
Innovating anemia care
for a better tomorrow
Oxemia (Desidustat) is India's 1st oral HIF-PHI approved for the treatment of anemia in adult patients with chronic kidney disease (CKD) on dialysis.
India's 1st oral
alternative to ESA
Proven efficacy in
raising & maintaining Hb
Oral convenience
once-daily dosing
Favorable safety
and tolerability profile
Effective Hb Response
88%of patients achieved Hb increase >= 1 g/dL
Mean Hb Increase
2.1g/dL from baseline
Patients Maintained Target Hb
76%maintained Hb 10-13 g/dL at 24 weeks
Data from Phase III trials in CKD patients on dialysis.
Understanding
anaemia in
chronic kidney
disease
When kidneys are not working as well as they should, the body may produce fewer red blood cells. Understanding the signs is the first step toward a better conversation.
Haemoglobincarries oxygen
O2Oxygen
HbRed blood cells
CKDKidney health
Lower haemoglobin
CKD may reduce the body’s natural erythropoietin production.
Daily impact
Fatigue and breathlessness can disrupt everyday routines.
Track your Hb
Regular monitoring can help guide the right management approach.
Common symptomsNotice the signs.
Notice the signs.
Start the conversation.
Shortness of breath
Difficulty concentrating
Low energy
Personalized dosing.
Optimized outcomes.
Oxemia dosing is titrated based on Hb response and CKD stage to help achieve and maintain target Hb with minimal dose adjustments.
Doctor Recommendation
Titrate dose gradually to achieve target Hb and avoid rapid increases.
Individualize based on response and tolerability.
1
Select CKD Stage
2
Recommended Starting Dose
CKD Stage
25 mg
50 mg
100 mg
Stage 5 ND
Once daily
Once daily
Once daily
3
Titration Flow
Start
Choose starting dose based on CKD stage and Hb level.
Assess
Reassess Hb every 2–4 weeks.
Adjust
Increase or decrease dose by 25 mg increments.
Maintain
Maintain target Hb 10–13 g/dL.
Note: Do not increase the dose more frequently than once every 2 weeks.
Personalized care
Dose tailored to CKD stage and patient response.
Better outcomes
Helps achieve target Hb with minimal adjustments.
Evidence-based approach
Titration guided by Hb levels and clinical response.
Patient focused
Improves safety, tolerability and quality of life.
Safety & UseUsing OXEMIA®
Using OXEMIA®
safely and effectively
OXEMIA® (Desidustat) is a prescription-only medicine. The summary below explains how to take it and what to be aware of - it does not replace the advice of your doctor or pharmacist.
Always read the full prescribing information and follow your healthcare professional's instructions.
How to take it
Take as prescribed
Use OXEMIA® in the dose and for the duration advised by your doctor - typically once daily.
Swallow whole
Swallow the tablet whole with water. Do not chew, crush or break it.
On an empty stomach
Take it on an empty stomach, unless your doctor advises otherwise.
If you miss a dose
Take it as soon as you remember. Skip it if your next dose is near - never take a double dose to make up.
Common side effects
Most side effects are mild and tend to settle as your body adjusts to treatment. Tell your doctor if any persist, worsen, or concern you.
Abdominal pain Vomiting Fever Weakness Peripheral swelling (oedema) Headache
Safety advice
Alcohol
CautionIt is not known whether alcohol is safe to consume with OXEMIA®. Please consult your doctor.
Pregnancy
ConsultSafety during pregnancy has not been established. Consult your doctor before use.
Breastfeeding
ConsultInformation on use while breastfeeding is not available. Please consult your doctor.
Driving
Usually safeOXEMIA® does not usually affect your ability to drive.
Kidney disease
CautionLimited data are available in patients with kidney disease. Use under medical supervision.
Liver disease
CautionLimited data are available in patients with liver disease. Use under medical supervision.
Store below 30°C
Keep in the original pack, away from heat and moisture, and out of the reach of children.
Prescription only
OXEMIA® is a prescription-only medicine. Use it only on the advice of a registered doctor.
Not habit-forming
OXEMIA® has no known habit-forming potential.
Regular monitoring
Your doctor may order blood tests to check haemoglobin, blood counts and electrolytes such as potassium.
Read the full prescribing information
Composition, indication, dosing, administration, warnings and storage in one document.
Evidence that
empowers confidence
Robust clinical data from Phase III trials demonstrate the efficacy and safety of Desidustat in CKD patients on dialysis.
Phase III trial data
Proven Hb improvement
Well tolerated safety profile
Published in peer-reviewed journals
Mean Hb Change Over Time
DesidustatEpoetin Alfa
Data from Phase III trials in CKD patients on dialysis.Publications
Desidustat in non-dialysis CKD patients: A randomized study
2022;32(4):323–330
Efficacy and safety of desidustat in dialysis patients
2022;16(8):OC01–OC05
HIF-PHI therapy: A new era in anaemia management
2021;36(3):405–413
FAQs
Clear answers.
Better conversations.
Find practical information about OXEMIA®, Desidustat, and anaemia management in CKD.
This information does not replace advice from your healthcare professional.
OXEMIA® contains Desidustat, an oral HIF-PH inhibitor developed for the management of anaemia associated with chronic kidney disease.
Still have a question?
Our medical information team is here to help.
We're here
to help.
For product information, prescribing resources, or medical enquiries, connect with the appropriate Oxemia team.
How can we support you?
For healthcare professionals
Access detailed prescribing information and medical resources.